Clinical data from the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide, independent of weight loss
Carry a letter from your prescribing provider that includes the medication name, the reason for the prescription, and the expected duration of your trip
Patients with risk factors for pancreatitis, gallbladder disease, or significant diabetic retinopathy require particular attention during treatment
In clinical practice, GLP-1 receptor agonists are used to manage type 2 diabetes and increasingly for weight-loss or metabolic indications
the first ever generic GLP-1 product specifically indicated for weight loss." Ernie Richardsen, Senior Vice President, Teva Pharmaceuticals Despite their potential, only about 4% of eligible individuals currently receive these prescriptions
Recent antibiotic use combined with GLP-1 therapy may increase the risk of digestive disturbances and should be mentioned to your healthcare provider